“Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial”
A common long-term side effect of anti-rejection (immunosuppressant) medications is skin cancer. This pilot clinical trial evaluates the feasibility of conducting a larger pivotal trial to examine the efficacy and safety of nicotinamide for prevention of keratinocyte carcinoma in solid organ transplant recipients. This pilot trial will transition into the pivotal trial if all feasibility targets are met.
Drug - Nicotinamide
Oral nicotinamide (500 mg) twice daily for at least 52 weeks
Drug - Placebo oral capsule
Matching placebo taken twice daily for at least 52 weeks
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: A Pilot, Placebo-controlled, Randomized Trial